November 7, 2019

Carl Firth, Ph.D.
Chief Executive Officer
ASLAN Pharmaceuticals Ltd.
83 Clemenceau Avenue #12-03 UE Square
Singapore

       Re: ASLAN Pharmaceuticals Ltd.
           Registration Statement on Form F-3
           Filed October 31, 2019
           File No. 333-234405

Dear Dr. Firth:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Paul Fischer at 202-551-3415 with any questions.



                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:    Robert Phillips